Long-Term Outcomes of Scleroderma Renal Crisis PDF Print E-mail
Wednesday, 17 March 2010 13:59
Virginia D. Steen, MD, and Thomas A. Medsger Jr., MD
Published: October 17th, 2000

Background: Although scleroderma renal crisis, a complication of systemic sclerosis, can be treated with angiotensin-converting enzyme (ACE) inhibitors, its long-term outcomes are not known.

Objective: To determine outcomes, natural history, and risk factors in patients with systemic sclerosis and scleroderma renal crisis.

Design: Prospective observational cohort study.

Setting: University program specializing in scleroderma.

Patients: 145 patients with scleroderma renal crisis who received ACE inhibitors and 662 patients with scleroderma who did not have renal crisis.

Measurements: Among patients with renal crisis, the four outcomes studied were no dialysis, temporary dialysis, permanent dialysis, and early death. Demographic, clinical, and laboratory data were compared to identify risk factors for specific outcomes. Follow-up was 5 to 10 years.

Results: 61% of patients with renal crisis had good outcomes (55 received no dialysis, and 34 received temporary dialysis); only 4 of these (4%) progressed to chronic renal failure and permanent dialysis. More than half of the patients who initially required dialysis could discontinue it 3 to 18 months later. Survival of patients in the good outcome group was similar to that of patients with diffuse scleroderma who did not have renal crisis. Some patients (39%) had bad outcomes (permanent dialysis or early death). Conclusions: Renal crisis can be effectively managed when hypertension is aggressively controlled with ACE inhibitors. Patients should continue taking ACE inhibitors even after beginning dialysis in hopes of discontinuing dialysis.

Scleroderma renal crisis (1) is defined as the new onset of severe hypertension associated with a rapid increase in serum creatinine concentration, microangiopathic hemolytic anemia, or both. Outcomes of this disorder, a once-fatal complication of scleroderma, have dramatically improved with the use of angiotensin-converting enzyme (ACE) inhibitors (1). We examined short- and long-term outcomes
of renal crisis in patients taking these medications...

To continue reading the full article, please login in and download from the link provided below.

 
More articles :

» U.S. Legislation Passed to Promote Research and Awareness of Scleroderma

(U.S.) has applauded the U.S. House of Representatives for the passage of the Scleroderma Research and Awareness Act (H.R. 2408), introduced last March by Rep. Lois Capps (D-CA) and Rep. Vern Ehlers (R-MI). This bipartisan legislation gives hope to...

» Quality Indicator Set for Systemic Sclerosis

D. Khanna, O. Kowal-Bielecka, P.P. Khanna, A. Lapinska, S.M. Asch, N. Wenger, K.K. Brown, P. Clements, T. Getzug, M.D. Mayes, T.A. Medsger Jr., R. Oudiz, R. Simms, V. Steen, P. Maranian, D.E. FurstBackground:Systemic sclerosis (SSc) is associated...

» New, Non-invasive Test May Help Diagnose Pulmonary Hypertension in Scleroderma

In patients with Systemic Sclerosis (SSc) – or – a condition called pulmonary hypertension (PH) is a leading cause of death. Having PH means the blood pressure between the heart and lungs is elevated.The Need for New Tests for PH in SScThe...

» Researchers Gain Deeper Insights Into Causes And New Treatment Strategies For Scleroderma

Using mice, lab-grown cells and clues from a related disorder, Johns Hopkins researchers have greatly increased understanding of the causes of , showing that a critical culprit is a defect in the way certain cells communicate with their structural...

» Genetic Accelerator Linked To Most Severe Cases of Lupus

A "genetic accelerator" is responsible for the most severe cases of Lupus (), an autoimmune disease: the accelerator, called enhancer HS1.2, speeds up the activity of some critical genes of the immune system involved in the disease.A team of Italian...

» New Study Shows Increased Risk Of Cancer In Scleroderma

patients have a 75% increased risk of cancer compared to the general population, a meta-analysis confirms, leading the authors to recommend screening in these patients.Patients were at particular risk of developing (RR 4.35) and haematological...